Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-08-02
2005-08-02
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S233800, C514S301000, C544S061000, C544S127000, C546S114000
Reexamination Certificate
active
06924283
ABSTRACT:
The invention provides a compound of formula I:wherein R1, R2, R3, and R4have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of treating a herpesvirus infection, atherosclerosis or restenosis using such compounds or salts.
REFERENCES:
patent: 4125611 (1978-11-01), Yamade et al.
patent: 4145418 (1979-03-01), Kuwada et al.
patent: 4767766 (1988-08-01), Baker et al.
patent: 4877793 (1989-10-01), Davies
patent: 4938949 (1990-07-01), Borch et al.
patent: 4959363 (1990-09-01), Wentland
patent: 5155115 (1992-10-01), Suzuki et al.
patent: 5219864 (1993-06-01), Suzuki et al.
patent: 5352685 (1994-10-01), Maruyama et al.
patent: 5593943 (1997-01-01), Nuebling et al.
patent: 5817819 (1998-10-01), Furuya et al.
patent: 6239142 (2001-05-01), Schnute et al.
patent: 6620810 (2003-09-01), Thorarensen
patent: 4227747 (1994-02-01), None
patent: 0046990 (1982-03-01), None
patent: 0269295 (1988-06-01), None
patent: 0443568 (1991-08-01), None
patent: 505058 (1992-09-01), None
patent: 0560348 (1993-09-01), None
patent: 2289276 (1995-11-01), None
patent: 46-032198 (1971-09-01), None
patent: 57116077 (1982-07-01), None
patent: 57142985 (1982-09-01), None
patent: 07076586 (1995-03-01), None
patent: 8143573 (1996-06-01), None
patent: 08301849 (1996-11-01), None
patent: 9208496 (1997-08-01), None
patent: WO-92/03427 (1992-03-01), None
patent: WO-95/28405 (1995-10-01), None
patent: WO-96/18616 (1996-06-01), None
patent: WO-96/18617 (1996-06-01), None
patent: WO-97/40846 (1997-11-01), None
patent: WO-98/11073 (1998-03-01), None
patent: WO-99/32450 (1999-07-01), None
patent: WO-99/62908 (1999-12-01), None
patent: WO-00/07595 (2000-02-01), None
patent: WO-00/40561 (2000-07-01), None
patent: WO-00/40563 (2000-07-01), None
patent: WO-00/53610 (2000-09-01), None
patent: WO-00/76990 (2000-12-01), None
patent: WO-01/37824 (2001-05-01), None
patent: WO-01/58898 (2001-08-01), None
patent: WO-03/020729 (2003-03-01), None
patent: WO-03/020730 (2003-03-01), None
1,4-dihydro-4-oxo[1]benzothieno[3,2-b]pyridine-3-carboxylate,Pharmazie, vol. 55, No. 8, (2000), pp. 595-600.
Nishikawa, Yoshinori, et al., “Synthesis and Antiallergic Activity of N-[4-(4-Diphenylmethyl-1-piperazinyl)butyl]-1,4-dihydro-4-oxopyridine-3-carboxamides”,Chem. Pharm. Bull., vol. 37, No. 5, (1989), pp. 1256-1259.
Patani, G. A., et al., “Bioisosterism: A Rational Approach in Drug Design”,Chem. Rev., vol., 96, (1996), pp. 3147-3176.
Revel, L., et al., “MKC-733”,Drugs of the Future, vol. 24, No. 9, (1999), pp. 966-968.
Vaillancourt, V. A., et al., “Naphthalene Carboxamides as Inhibitors of Human Cytomegalovirus DNA Polymerase”,Bioorganic&Medicinal Chemistry Letters, vol. 10, (2000), pp. 2079-2081.
Blaskiewicz, Peter.,“Thienopyridinonecarboxylic Acid Derivatives”.
Thornber, C. W. ,“Isosterism and Molecular Modification in Drug Design”,Chemical Society Review, vol. 8, No. 4, (1979),pp. 563-580.
Database Crossfire Beilstein, vol. 26, No. 1, Beilstein Institut zur Foerderung der Chemischen Wissenschaften, Beilstein Registry No. 4321837, (1999), 3 pages.
Database Crossfire Beilstein, vol. 21, Beilstein Institut zur Foerderung der chemischen Wissenschaften, Beilstein Registry No. 4381517, (1984), 3 pages.
The Merck Manual of Diagnosis and Therapy, Eleventh Edition, Lyght, C.E., et al., (eds.), Merck & Co., (1966), p. 212-213.
Elliott, Richard L., et al., “The Preparation of 2-(Heterocyclyl)thieno[3,2-b]pyridine Derivatives”,Tetrahedron, vol. 43, No. 14, (1987), pp. 3295-3302.
Goerlitzer, K., et al., Gyrase inhibitors; Part 3.: Synthesis and reactions of ethyl.
McKane Joseph K.
Pfizer
Saeed Kamal
Schwegman Lundberg Woessner & Kluth P.A.
LandOfFree
4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3479725